Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid Β 25-35 -induced toxicity in mice

Neuropsychopharmacology

Volumn 34, Issue 6, 2009, Pages 1552-1566

  Villard, Vanessa ^a,b,c   Espallergues, Julie ^a,b,c   Keller, Emeline ^a,b,c   Alkam, Tursun ^d,e   Nitta, Atsumi ^d   Yamada, Kiyofumi ^d   Nabeshima, Toshitaka ^d,f   Vamvakides, Alexandre ^g   Maurice, Tangui ^a,b,c  

^a University of Montpellier   (France)

^b UNIV MONTPELLIER   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Department of Basic Medicine   (China)

^f MEIJO UNIVERSITY   (Japan)

^g Anavex Life Sciences ^*  (Greece)

Author keywords

Amyloid toxicity; Learning and memory; Muscarinic ligand; Oxidative stress; S1 protein ligand

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ANAVEX1 41; CASPASE 3; CASPASE 9; FURAN DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; MUSCARINIC RECEPTOR; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; SCOPOLAMINE; SIGMA 1 OPIATE RECEPTOR; TETRAHYDRO N,N DIMETHYL 5,5 DIPHENYL 3 FURANMETHANAMINE HYDROCHLORIDE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIORAL RESEARCH; BRAIN CORTEX; BRAIN PROTECTION; CELL COUNT; CELL LEVEL; CELL LOSS; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TARGETING; ENCEPHALITIS; HIPPOCAMPUS; LEARNING DISORDER; LIMBIC SYSTEM; LIPID PEROXIDATION; MALE; MENTAL PERFORMANCE; MOUSE; NEUROTOXICITY; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; SPATIAL MEMORY; TISSUE STRUCTURE; WORKING MEMORY;

AMYLOID BETA-PROTEIN; ANIMALS; AVOIDANCE LEARNING; BRAIN; CASPASE 3; CASPASE 9; CELL DEATH; ETHYLENEDIAMINES; FURANS; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; LEARNING DISORDERS; LIPID PEROXIDATION; MALE; MEMORY; MEMORY DISORDERS; MICE; MUSCARINIC ANTAGONISTS; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; SCOPOLAMINE; SPACE PERCEPTION;

EID: 64949103489     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.212     Document Type: Article

References (52)

1. Abramov AY, Canevari L, Duchen MR (2004). βb-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24: 565-575.
2. 25-35. Behav Brain Res 180: 139-145.
3. Anagnostaras SG, Maren S, Fanselow MS (1995). Scopolamine selectively disrupts the acquisition of contextual fear conditioning in rats. Neurobiol Learn Mem 64: 191-194.
4. Behl C, Davis JB, Lesley R, Schubert D (1994). Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77: 817-827.
5. Chafekar SM, Baas F, Scheper W (2008). Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta 1782: 523-531.
6. 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal 9: 2245-2254.
7. Delobette S, Privat A, Maurice T (1997). In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol 319: 1-4.
8. Dong Y, Fu YM, Sun JL, Zhu YH, Sun FY, Zheng P (2005). Neurosteroid enhances glutamate release in rat prelimbic cortex via activation of α1-adrenergic and s1 receptors. Cell Mol Life Sci 62: 1003-1104.
9. Eckerman DA, Gordon WA, Edwards JD, MacPhail RC, Gage MI (1980). Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat. Pharmacol Biochem Behav 12: 595-602.
10. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R et al (2002). Neuroinflammation in Alzheimer's disease and prion disease. Glia 40: 232-239.
11. 1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41. Br J Pharmacol 152: 267-279.
12. Fang F, Liu GT (2006). Protective effects of compound FLZ on b-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharmacol Sin 27: 651-658.
13. Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R et al (1991). (+-)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 257: 392-403.
14. Frederickson RC (1992). Astroglia in Alzheimer's disease. Neurobiol Aging 13: 239-253.
15. Ghelardini C, Galeotti N, Matucci R, Bellucci C, Gualtieri F, Capaccioli S et al (1999). Antisense 'knockdowns' of M1 receptors induce transient anterograde amnesia in mice. Neuropharmacology 38: 339-348.
16. 25-35 oligomers, S100 β and neurotransmitters. J Neuroimmunol 186: 181-192.
17. Hayashi T, Su TP (2001). Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci USA 98: 491-496.
18. 1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmen-talization and export. J Pharmacol Exp Ther 306: 718-725.
19. 2+ signaling and cell survival. Cell 131: 596-610.
20. 3H-acetylcholine from striatal and hippocampal rat brain slices. Synapse 46: 1-3.
21. 1-42 impairs endogenous antioxidant systems in vivo. Neuroscience 119: 399-419.
22. 25-35. Neuroscience 145: 209-224.
23. 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70: 474-483.
24. 25-35-induced neurodegeneration. Eur J Neurosci 23: 1417-1426.
25. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ (1995). Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15: 4077-4092.
26. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G (2005). Neuroprotective effects of sigma-1 receptor agonists against β-amyloid-induced toxicity. Neuroreport 16: 1223-1226.
27. Matsuno K, Senda T, Kobayashi T, Mita S (1995). Involvement of sigma1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res 60: 200-206.
28. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992). β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389.
29. 1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 84: 581-597.
30. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
31. 25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 83: 413-428.
32. 1 receptor. Br J Pharmacol 149: 998-1012.
33. Miyakawa T, Yamada M, Duttaroy A, Wess J (2001). Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21: 5239-5250.
34. Monnet FP, Debonnel G, de Montigny C (1992). In vivo electrophysiological evidence for a selective modulation of N-methyl-D- aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261: 123-130.
35. 1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci 100: 93-118.
36. 1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci USA 96: 8196-8199.
37. 2 muscarinic acetylcholine receptors. J Neurochem 96: 510-519.
38. 1 agonist, on the impaired working memory in AF64A-treated rats. Jpn J Pharmacol 51: 539-547.
39. 25-35 are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 108: 1065-1079.
40. 2-muscarinic receptor antagonist in aged memory-impaired. J Neurosci 15: 1455-1462.
41. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J et al (2004). M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24: 10117-10127.
42. Selkoe DJ (1989). Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease. Neurobiol Aging 10: 387-395.
43. Selkoe DJ (2004). Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6: 1054-1061.
44. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657.
45. 25-35 peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 61: 197-205.
46. Stepanichev MY, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV (2006). Studies of the effects of central administration of β-amyloid peptide (25-35): pathomorphological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36: 101-106.
47. 25-35-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav 80: 647-655.
48. Su TP, Wu XZ, Cone EJ, Shukla K, Gund TM, Dodge AL et al (1991). Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther 259: 543-550.
49. Sutherland RJ, Whishaw IQ, Regehr JC (1982). Cholinergic receptor blockade impairs spatial localization by use of distal cues in the rat. J Comp Physiol Psychol 96: 563-573.
50. Um MY, Choi WH, Aan JY, Kim SR, Ha TY (2006). Protective effect of Polygonum multiflorum Thunb on amyloid β-peptide 25-35 induced cognitive deficits in mice. J Ethnopharmacol 104: 144-148.
51. Vamvakides A (2002). Mechanism of action of tetrahydro-N,N- dimethyl-5,5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound. Ann Pharm Fr 60: 415-422.
52. Walsh DM, Klyubin I, Fadeeva JW, Cullen WK, Anwyl R, Wolfe MS et al (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.